BEIJING, March 13 (Xinhua) -- Two reports approved Tuesday at the third session of the 14th National People's Congress were released in full via Xinhua News Agency on Thursday.

本资料为强生创新制药所有，仅供医学药学专业人士参考，未经批准，严禁翻印、转载及传播。 本资料仅用于医学、科学交流，可能涉及尚未在中国获批的产品和适应症。强生创新制药不支持、不鼓励任何未被批准的药品/适应症使用。

BEIJING, March 12 (Xinhua) -- The following is the full text of the government work report delivered at the third session of the 14th National People's Congress of the People's Republic of China on ...

Entrusted by the session's presidium, Li Hongzhong, executive chairperson of the presidium, presided over the meeting ...

South Korea's court on Friday approved the release of the arrested President Yoon Suk-yeol, according to multiple media ...

本资料为强生创新制药所有，仅供医学药学专业人士参考，未经批准，严禁翻印、转载及传播。 本资料仅用于医学、科学交流，可能涉及尚未在中国获批的产品和适应症。强生创新制药不支持、不鼓励任何未被批准的药品/适应症使用。

2024下半年至今，希维奥陆续在泰国、马来西亚、印度尼西亚获批上市，大幅推进了公司在亚太市场的商业化布局。截至目前，希维奥已在亚太市场的10个国家和地区获批用于治疗多项适应症。